Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

@article{Schildkraut2002ImpactOP,
  title={Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.},
  author={Joellen Martha Schildkraut and Brian Calingaert and Polly A. Marchbanks and Patricia G. Moorman and Gustavo C. Rodriguez},
  journal={Journal of the National Cancer Institute},
  year={2002},
  volume={94 1},
  pages={32-8}
}
BACKGROUND Oral contraceptive (OC) use is associated with a reduced risk of developing ovarian cancer, but the mechanism for the risk reduction has not been well defined. In this study, we investigate the relationship between the progestin and estrogen potency in combination OCs and the risk of developing ovarian cancer. METHODS The study included 390 case subjects with epithelial ovarian cancer and 2865 control subjects, between 20 and 54 years of age, identified from the Cancer and Steroid… CONTINUE READING